CHRS | Coherus Biosciences Inc
Category: Consumer goods
Quick infos Headquarters: Redwood City, California, United States Trade prices Volume: Market Cap: 606.22M Prev closed: Open: 17.25 High: 17.48 Low: 16.47 52 week low: 12.21 52 week high: 22.22 Dividends: No Dividends Next ER: March 6, 2023 After Market Closes
Company Profile Coherus BioSciences, Inc. is a leading global biologics platform company focused on delivering high-quality biosimilar therapeutics that may expand patient access to life-changing medicines in regulated markets worldwide. In 2018, the U.S. Food and Drug Administration approved Coherus? biosimilar UDENYCA® (pegfilgrastim-cbqv). Coherus is headquartered in the heart of California?s Silicon Valley and composed of a team of industry veterans with decades of experience pioneering biologics companies.
Earnings History Date EPS / Forecast Revenue / Forecast May 11, 2023 March 6, 2023 -0.6 / -0.845.35M / 48.41MNovember 8, 2022 -0.96 / -0.7445.4M / 57.27MAugust 4, 2022 -0.65 / -0.783860.15M / 62.04MMay 5, 2022 -1.24 / -0.646760.12M / 69.54Mview more
Historical Data Date Price Open High Low Vol Change ER Aug 4, 2022 10.58 9.95 10.81
9.95
1.39M 5.17% Aug 3, 2022 10.06 10.14 10.75
9.93
1.92M 0.40% Aug 2, 2022 10.02 9.15 10.05
9.04
1.17M 9.39% Aug 1, 2022 9.16 8.48 9.38
8.39
1.24M 8.15% Jul 29, 2022 8.47 8.42 8.50
8.06
781.80K 0.36% Jul 28, 2022 8.44 8.11 8.51
7.71
963.04K 4.33% Jul 27, 2022 8.09 7.51 8.11
7.41
1.02M 8.88% Jul 26, 2022 7.43 7.24 7.58
7.09
924.48K 1.78% Jul 25, 2022 7.30 7.20 7.31
6.98
859.85K 1.81% Jul 22, 2022 7.17 7.88 7.89
7.14
1.84M -9.01% view more
NASDAQ - Nasdaq Stock Market
More profiles and info about the company Founded:2010 Employees:291 News
Coherus BioSciences to Present at Upcoming Investor Conferences in March finance.yahoo.com Mar 1, 2023 8:25 am Coherus touts late-stage toripalimab overall survival data in nasopharyngeal carcinoma seekingalpha.com Feb 15, 2023 11:30 pm
Coherus and Junshi Biosciences Announce Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Clinical Trial Evaluating Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma finance.yahoo.com Feb 15, 2023 8:25 am
Coherus BioSciences Announces New Employment Inducement Grants finance.yahoo.com Feb 3, 2023 5:30 pm Junshi's toripalimab meets main goal of late-stage study in lung cancer subtype seekingalpha.com Jan 18, 2023 6:36 pm Coherus stock dips amid deal to acquire US rights to Eylea biosimilar FYB203 seekingalpha.com Jan 10, 2023 12:16 am
Coherus Agrees to Acquire Exclusive U.S. Commercial Rights to Eylea® Biosimilar FYB203 from Klinge Biopharma finance.yahoo.com Jan 9, 2023 8:20 am
Should You Invest in Coherus BioSciences (CHRS)? finance.yahoo.com Jan 3, 2023 7:12 am Coherus down 10% on BLA action date delay for toripalimab seekingalpha.com Dec 28, 2022 12:02 am Junshi inks licensing deal with Hikma for toripalimab; FDA filing still under review seekingalpha.com Dec 27, 2022 6:23 pm Coherus sheds 13% on FDA action date for cancer drug seekingalpha.com Dec 24, 2022 4:12 am
Coherus and Junshi Biosciences Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) finance.yahoo.com Dec 24, 2022 12:01 am
Coherus BioSciences Reports First Quarter 2022 Results finance.yahoo.com Dec 20, 2022 4:01 pm FDA Approves Coherus' Version of Abbvie's Humira, Best-Selling Drug in the U.S. thestreet.com Dec 20, 2022 5:36 am
Coherus BioSciences Reports Second Quarter 2022 Results and Provides Business Update finance.yahoo.com Dec 20, 2022 4:01 pm
Coherus BioSciences Reports Third Quarter 2022 Results and Provides Business Update finance.yahoo.com Dec 20, 2022 4:01 pm
Shareholders in Coherus BioSciences (NASDAQ:CHRS) have lost 61%, as stock drops 12% this past week finance.yahoo.com Dec 20, 2022 9:47 am
Orion Capital Management LLC Buys Qualcomm Inc, Distillate U.S. ... finance.yahoo.com Dec 20, 2022 9:38 am
FDA Rejects Junshi - Coherus' Toripalimab For Rare Head & Neck Cancer finance.yahoo.com Dec 20, 2022 9:22 am
Coherus BioSciences to Report First Quarter 2022 Financial Results on May 5th, 2022 finance.yahoo.com Dec 20, 2022 8:45 am This company doesn't provide a dividend.
Talk about Coherus Biosciences Inc below in comments section below. Do you think you'll buy? Do you already have active trades now?
EarningsAhead is not affiliated with and this is not an endorsement of the companies featured above.
Share it with fellow traders:
or join discussions in FB below
(
FB comments )
If you are looking for News & events, Press Release, they are available on their Investors Relations site.
Consensus
If you want to help pay for server cost or for improving this tool. You can send it via Paypal .
Buy on Amazon Graham's philosophy of "value investing" has made The Intelligent Investor the stock market bible ever since its original publication in 1949.
The best book on investing ever written.
